カテゴリ： GlobalData, イギリス, 企業調査

Abzena Plc (ABZA)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Abzena Plc (ABZA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8013126
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月27日
◆ページ数：77
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：イギリス
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Abzena Plc (Abzena), formerly Polytherics Group Ltd is a life science company that provides complementary services and technologies to enable the selection, development and manufacture of biopharmaceuticals products based on antibodies and other proteins. The company’s technologies include antibody discovery and candidate screening, immunology and immunogenicity assessment, manufacture of payload linkers and antibody drug conjugates, development of manufacturing cell lines and process development, and others. Abzena provides its services to biopharmaceutical companies, public and private biotech companies and academic groups, among others. It has its presence in the UK and the US. Abzena is headquartered in Cambridge, the UK.

Abzena Plc (ABZA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Abzena Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Abzena Plc, Medical Devices Deals, 2011 to YTD 2017 11
Abzena Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Abzena Plc, Pharmaceuticals & Healthcare, Deal Details 15
Venture Financing 15
Abzena Raises Funds through Venture Financing 15
PolyTherics Secures US$3.5 Million In Series B Financing 17
Partnerships 18
Abzena Enters into Agreement with Enleofen Bio 18
Abzena Partners with UGA Biopharma 19
Abzena and Baylor Scott & White Research Institute Form Joint Venture 20
Abzena Enters into Agreement with Apitope 21
Antitope Extends Research Agreement with ANRS, INSERM and Baylor Research Institute 22
PolyTherics Enters into Agreement with Alpha Cancer to Produce Tumor Targeting Drug Conjugate Pact 23
PolyTherics Extends Agreement With MacroGenics To Produce Antibody Drug Conjugates 24
Antitope Enters Into Research Agreement With Annexon For Therapeutic Antibodies 25
Tube Pharma Enters into Co-Development Agreement with PolyTherics for Antibody Drug Conjugates 26
Antitope Enters Into Research Agreement With ChemomAb For Composite Human Antibodies 27
Antitope Enters Into Co-Development Agreement With Research Corporation Technologies For Therapeutic Protein 28
Antitope Enters Into Co-Development Agreement With Eden Biodesign For Therapeutic Antibodies 29
Antitope Enters Into Research Agreement With NeuroPhage Pharma 30
Biotecnol Enters Into Co-Development Agreement With PolyTherics For Tribody Drug Conjugates 31
PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 32
Antitope Enters Into Research Collaboration With Therapure Biopharma 33
Antitope Enters Into Co-Development Agreement With Kolltan Pharma 34
Antitope Enters Into Co-Development Agreement With The University Of North Carolina 35
Antitope Enters Into Co-Development Agreement With IMMIH 36
Antitope Enters Into Research Collaboration With NasVax 37
Cellmid Enters into Agreement with Antitope 38
PolyTherics Enters Into Drug Development Agreement With Critical Pharma 39
Licensing Agreements 40
Telix Pharma Enters into Licensing Agreement with Abzena 40
OBI Pharma Enters into Licensing Agreement with Abzena 41
Abzena Enters into Licensing Agreement for ThioBridge 42
Trieza Therapeutics Enters into Licensing Agreement with Abzena 43
ProtAb Enters into License Agreement with Antitope 44
Abzena Enters into Licensing Agreement for Thiobridge ADC Linker Technology 45
Antitope Enters into Licensing Agreement with University College London for Humanized Antibodies 46
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Technology 47
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor IX 48
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor VIIa 49
Nuron Biotech Exercises Option Licensing Agreement With PolyTherics 50
Equity Offering 51
Abzena Raises USD31 Million in Private Placement of Shares 51
Abzena Raises Funds through Private Placement of Shares upon Exercise of Warrants 52
Abzena Raises USD31.8 Million in Private Placement of Shares 53
Abzena Completes IPO 54
Acquisition 55
Abzena Acquires The Chemistry Research Solution for USD15 Million 55
Abzena Acquires PacificGMP 56
PolyTherics Acquires Antitope For US$20.7 Million 58
Abzena Plc – Key Competitors 59
Abzena Plc – Key Employees 60
Abzena Plc – Locations And Subsidiaries 61
Head Office 61
Other Locations & Subsidiaries 61
Joint Venture 61
Recent Developments 62
Financial Announcements 62
Jun 13, 2017: Abzena Announces Full year results: integration and growth seen across the Group, with 41% underlying increase in revenues 62
Feb 21, 2017: Abzena: Trading and business update 63
Nov 30, 2016: Abzena announce Half year results: Integrated service offering driving revenue growth 65
Jun 14, 2016: Abzena Announces Full Year Results: Eevenues up 74%, Strong Outlook Within Growing Market 69
Corporate Communications 70
Oct 24, 2016: Abzena makes two senior executive appointments to drive growth of international business 70
Sep 13, 2016: Abzena Announces Directorate change 71
Government and Public Interest 72
Mar 02, 2017: Abzena, UCL secure £3.5m grant from MRC for autoimmune therapy research 72
Jan 18, 2016: Eurostars grant awarded to international consortium including Abzena company, Antitope, for development of novel treatment for clotting disorders 73
Other Significant Developments 74
Nov 14, 2017: Novel Antibodies against a Ground-Breaking New Target for the Treatment of Cardiovascular Fibrosis Developed by Enleofen Bio, with Support from Abzena, Featured in ‘Nature’ Article 74
Mar 09, 2016: Abzena provides Business update – strong second half momentum 75
Appendix 77
Methodology 77
About GlobalData 77
Contact Us 77
Disclaimer 77

List of Tables
Abzena Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Abzena Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Abzena Plc, Deals By Therapy Area, 2011 to YTD 2017 10
Abzena Plc, Medical Devices Deals, 2011 to YTD 2017 11
Abzena Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Abzena Raises Funds through Venture Financing 15
PolyTherics Secures US$3.5 Million In Series B Financing 17
Abzena Enters into Agreement with Enleofen Bio 18
Abzena Partners with UGA Biopharma 19
Abzena and Baylor Scott & White Research Institute Form Joint Venture 20
Abzena Enters into Agreement with Apitope 21
Antitope Extends Research Agreement with ANRS, INSERM and Baylor Research Institute 22
PolyTherics Enters into Agreement with Alpha Cancer to Produce Tumor Targeting Drug Conjugate Pact 23
PolyTherics Extends Agreement With MacroGenics To Produce Antibody Drug Conjugates 24
Antitope Enters Into Research Agreement With Annexon For Therapeutic Antibodies 25
Tube Pharma Enters into Co-Development Agreement with PolyTherics for Antibody Drug Conjugates 26
Antitope Enters Into Research Agreement With ChemomAb For Composite Human Antibodies 27
Antitope Enters Into Co-Development Agreement With Research Corporation Technologies For Therapeutic Protein 28
Antitope Enters Into Co-Development Agreement With Eden Biodesign For Therapeutic Antibodies 29
Antitope Enters Into Research Agreement With NeuroPhage Pharma 30
Biotecnol Enters Into Co-Development Agreement With PolyTherics For Tribody Drug Conjugates 31
PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 32
Antitope Enters Into Research Collaboration With Therapure Biopharma 33
Antitope Enters Into Co-Development Agreement With Kolltan Pharma 34
Antitope Enters Into Co-Development Agreement With The University Of North Carolina 35
Antitope Enters Into Co-Development Agreement With IMMIH 36
Antitope Enters Into Research Collaboration With NasVax 37
Cellmid Enters into Agreement with Antitope 38
PolyTherics Enters Into Drug Development Agreement With Critical Pharma 39
Telix Pharma Enters into Licensing Agreement with Abzena 40
OBI Pharma Enters into Licensing Agreement with Abzena 41
Abzena Enters into Licensing Agreement for ThioBridge 42
Trieza Therapeutics Enters into Licensing Agreement with Abzena 43
ProtAb Enters into License Agreement with Antitope 44
Abzena Enters into Licensing Agreement for Thiobridge ADC Linker Technology 45
Antitope Enters into Licensing Agreement with University College London for Humanized Antibodies 46
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Technology 47
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor IX 48
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor VIIa 49
Nuron Biotech Exercises Option Licensing Agreement With PolyTherics 50
Abzena Raises USD31 Million in Private Placement of Shares 51
Abzena Raises Funds through Private Placement of Shares upon Exercise of Warrants 52
Abzena Raises USD31.8 Million in Private Placement of Shares 53
Abzena Completes IPO 54
Abzena Acquires The Chemistry Research Solution for USD15 Million 55
Abzena Acquires PacificGMP 56
PolyTherics Acquires Antitope For US$20.7 Million 58
Abzena Plc, Key Competitors 59
Abzena Plc, Key Employees 60
Abzena Plc, Subsidiaries 61
Abzena Plc, Joint Venture 61

★海外企業調査レポート[Abzena Plc (ABZA)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • BYD Co Ltd (1211)：企業の財務・戦略的SWOT分析
    BYD Co Ltd (1211) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Mita-Teknik AS：企業の戦略的SWOT分析
    Mita-Teknik AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Alviva Holdings Ltd (AVV)：企業の財務・戦略的SWOT分析
    Alviva Holdings Ltd (AVV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Boral Limited：企業の戦略・SWOT・財務情報
    Boral Limited - Strategy, SWOT and Corporate Finance Report Summary Boral Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Perpetual Limited (PPT)：企業の財務・戦略的SWOT分析
    Perpetual Limited (PPT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Central Iowa Power Cooperative：企業の戦略的SWOT分析
    Central Iowa Power Cooperative - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • TesoRx Pharma LLC：製薬・医療：M&Aディール及び事業提携情報
    Summary TesoRx Pharma LLC (TesoRx) is a pharmaceutical company that develops treatments to address unmet medical needs. The company’s product pipeline comprises TSD-001, TSD-005, TSX-011 and TSX-002. Its TSD-001is an intravesical paclitaxel for the treatment of non-muscle invasive bladder cancer. Te …
  • Aushon BioSystems Inc-医療機器分野：企業M&A・提携分析
    Summary Aushon BioSystems Inc (Aushon) is a medical device provider that offers biomarker measurement and analysis products. The company provides biomarker therapeutic areas in microarray printing technology. Its products include ciraplex assay, cirascan imaging and cirasoft analysis and cira servic …
  • Nuverra Environmental Solutions, Inc. (NES)-石油・ガス分野：企業M&A・提携分析
    Summary Nuverra Environmental Solutions, Inc. (Nuverra), formerly known as Heckmann Corporation, provides environmental solutions to customers focused on the development and ongoing production of oil and natural gas from shale formations. It provides environmental solutions, including delivery, coll …
  • Volkswagen AG (VOW3)-エネルギー分野：企業M&A・提携分析
    Summary Volkswagen AG (Volkswagen) is an automobile company involved in the design, development, production and sales of a wide range of vehicles and engines. It commercializes both passenger and commercial vehicles, including low consumption small cars and luxury class vehicles. The company sells i …
  • BP Plc (BP.)：石油・ガス：M&Aディール及び事業提携情報
    Summary BP Plc (BP) is an integrated oil and gas company. Its upstream activities include exploration, development and production of oil and natural gas, field development and production; and midstream operations include transportation, and marketing and trading of natural gas, including liquefied n …
  • AIB Group (UK) plc：企業の戦略的SWOT分析
    AIB Group (UK) plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • KemPharm Inc (KMPH)：企業の財務・戦略的SWOT分析
    Summary KemPharm Inc (KemPharm) is a clinical-stage specialty pharmaceutical company that offers discovery and development of proprietary new molecular entity prodrugs. The company’s product pipeline includes KP415, methylphenidate drug for ADHD; KP201/IR, KP511/ER, KP606/IR and KP746 drugs for the …
  • Isuzu Motors Ltd (7202)：企業の財務・戦略的SWOT分析
    Isuzu Motors Ltd (7202) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Yellowstone Valley Electric Cooperative, Inc.：企業の戦略的SWOT分析
    Yellowstone Valley Electric Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors …
  • Dell Technologies Inc (DVMT)：医療機器：M&Aディール及び事業提携情報
    Summary Dell Technologies, Inc. (Dell), is a provider of desktop personal computers, software and peripherals. The company designs, develops, manufactures, markets, sells and supports information technology infrastructure such as laptops, desktops, mobiles, workstations, storage devices and printers …
  • Dynasty Fine Wine Group Limited：企業の戦略・SWOT・財務分析
    Dynasty Fine Wine Group Limited - Strategy, SWOT and Corporate Finance Report Summary Dynasty Fine Wine Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Kangmei Pharmaceutical Co Ltd (600518)：製薬・医療：M&Aディール及び事業提携情報
    Summary Kangmei Pharmaceutical Co Ltd (Kangmei) is a manufacturer and distributor of herbal medicine. The company provides herbal raw materials and preparations. Kangmei products include Chinese herbal medicine, bottled single product, hong mei life, xinkaihe senate, chinese medicine derived, medici …
  • Hotels.com LP：企業の戦略・SWOT・財務情報
    Hotels.com LP - Strategy, SWOT and Corporate Finance Report Summary Hotels.com LP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Zeltiq Aesthetics Inc (ZLTQ)-医療機器分野：企業M&A・提携分析
    Summary Zeltiq Aesthetics Inc (Zeltiq), a subsidiary of Allergan Plc is a medical technology company that develops and commercializes products of cooling technology. The company offers CoolSculpting System utilizing proprietary controlled-cooling technology to selectively reduce stubborn fat bulges. …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆